ApconiX is delighted to welcome Dr Kimberly Rockley.  Kim has a strong research background in oncology and will work with the team of experts in nonclinical safety and toxicology at ApconiX.

Kim studied Biomedical Science and gained her bachelor’s degree and her master’s degree in Cancer Pharmacology at the University of Bradford, graduating with distinction. She went on to become a Clinical Trial Coordinator for Oncology at the Haematology and Oncology Centre, University Hospitals Bristol NHS foundation Trust in the UK before studying for a PhD Pharmacy at Durham University where her thesis title was “In Vitro Evaluation of Anthracycline-induced Cardiotoxicity and Mitigation by Perturbation of Angiotensin Signalling”

Kim was awarded the prestigious Durham doctoral studentship award and was supervised by Dr Jason Gill, current Reader in Molecular Therapeutics in the School of Pharmacy and the Northern Institute for Cancer Research, Newcastle University and Chair of the Scientific Subcommittee of the British Toxicology Society.

Professor Ruth Roberts, Director and Co-founder of ApconiX commented, “It’s great to have Kim joining us since she has an outstanding academic background and will bring new thinking and great ideas to the team.  Kim’s my ‘science grandchild’ – Jason was my PhD student not that long ago!’

Kim has received numerous prizes including best poster presentation at the 2016 BTS congress and the 2016 SPS junior investigator poster contest.  She studied her master’s with a scholarship from the Medicine Research Council.

“I am thrilled to be joining ApconiX.  Toxicology is such an important element of drug discovery and development.  Oncology and neurological science is a particular interest of mine, I am looking forward to learning so much more about many therapeutic areas from the toxicology experts that work at ApconiX,” added Kim.